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THE FAILURE OF CHLOROQUINE TO STIMULATE THE HUMAN
ADRENAL CORTEX*
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The estab]ishment of synthetic antimalarial
drugs as effective agents in the treatment of
light-sensitive dermatoses has aroused the interest
of investigators in the mechanism of their action.
Recent work with the guinea pig has indicated
that the mechanism of quinacrine might be an
indirect one—that quinacrine might serve to
stimulate adrenal cortical activity and that in-
creased production of adrenocortical hormones
might be directly responsible for clinical improve-
ment. The purpose of this paper is to report the
results of experiments designed to test the possi-
bility of this mechanism in human subjects.
Chloroquine (Aralen, SN-7618, 7-chloro-4-(4-
diethylamino, -1 -methylbutamino) quinoline) has
been chosen for this study because its thera-
peutic efficiency has been established as equal or
superior to that of quinacrine in both parasitic
and light-sensitive diseases, while it has fewer
toxic or undesirable properties.
THEn APEUTIC USES OF CHLOEOQUINE
A review of the medical applications of chloro-
quine will serve to introduce the presently known
data about its mode of action. The drug was
adopted by the United States Army in 1947 (1)
and maintains its position ten years later in the
United States Dispensatory (2) as tbe most ef-
fective and least toxic agent for the suppressive
therapy of malaria during exposure to infection.
In addition, it is the drug of choice iu the
treatment of hepatic amebiasis (3). It is also
highly effective in the treatment of leishmaniasis
(4). The light-sensitive dermatoses constitute a
second category in which the usefulness of chloro-
quine is well established. Clinical studies have
shown that it is the most effective single drug for
the treatment of chronic discoid lupus erythema-
tosus (5). It holds the same position in respect to
polymorphous light eruption, and is, in addition,
an effective prophylactic agent (6). A third cate-
gory comprises a number of diseases in which
ehloroquine has been tried, but in which its useful-
ness is questionable, erratic, or has not yet been
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established. A report of the successful treatment
of 10 of a series of 12 cases of larva migrans still
awaits confirmation by other clinicians (7). The
most extensive long-term study of chloroquine in
the therapy of rheumatoid arthritis (8) is moro
optimistic than convincing. Used in two cases of
auricular fibrillation (9), chloroquine was more
toxic and less satisfactory than quinidine. Derma-
tologic diseases in which ehloroquine has been
employed but has not won general acceptance
include—aerodermatitis chroniea atrophicans
(10), lichen planus and psoriasis (11), vitiligo
(12), rosaeea (13), and sareoidosis (14).
THE MECHANISM OF ACTION OF CHLOEOQUINE
Chloroquine on prolonged administl ation
tends to accumulate in the liver, spleen, kidney,
lungs, red cells, and white cells, in concentrations
200—700 times the plasma level. MeChesney,
et al. (15) have recently demonstrated that in
rats the skin contains t' the amount of ebloro-
quine found in the liver. Most of the ehloroquine
found in the skin is present in the cellular portion,
viz., epidermis (16). This cellular concentration
is generally attributed to the chemical affinity
between ehloroquine and nueleoproteins dis-
covered by Parker and Irvin (17). These authors
showed by spectrophotometrie analysis that
chloroquine is strongly bound to highly polymer-
ized beef spleen desoxypentose nueleoprotein and
desoxypentose nucleate. This relationship would
at least seem adequate to explain the tissue con-
centration phenomena and also suggests a
mechanism of antiparasitic action.
Chloroquine has been shown to interfere with
a number of biochemical systems. Its ability to
inhibit the L.E. phenomenon in vitro (18) is
thought by Kurniek to be a substrate-inhibition
of DNA-ase activity, caused by the aforemen-
tioned nucleic acid-binding property of the drug.
Haydn (19) believes that a rationale for ehloro-
quine therapy of rheumatoid arthritis can be
based on Loomis and Lipman's (20) demonstra-
tion that it can reversibly uncouple oxidative
phosphorylation. Dawes (21) was the first to
demonstrate the anti-cholinergie effects of
ehloroquine. Plasma eholinesterase is eompeti-
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TABLE 1
Tabulation of Effect of Chloroquine (750 mgm/day for J8 days)
Eight Normal Subjects
on the Eosinophile Count o•f
Subj. No. Eosinophiles/mm8
1 94 184 158 112 92 127 167 162 116 100 147 84 88 144 60 106
2 104 131 156 137 152 187 200 105 175 184 156 122 113 97 119
3 331 159 173 136 139 200 142 187 103 105 259 91 84 88 150 163
4 119 111 119 128 141 152 166 134 97 103 122 113 100 113 122
5 150 92 120 139 145 118 108 116 281 144 88 138 106 100 103 113
6 231 253 187 194 123 195 189 181 159 166 241 163 178 141 181 319
7 117 83 66 106 146 131 86 112 144 89 150 94 97 94 91 119
8 187 181 141 167 175 129 159 97 253 178 247 176 83 134 156 106
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FIG. 1. Graph of the effect of chioroquine (750
mgm/day for 28 days) on the eosinophile count of
eight normal subjects.
tively bound by chloroquine. Recent work by
Agarwal and Arora (22) has confirmed its
anticholinergic effect on cardiac and smooth
muscle, while that of Jindal (23) has shown that
it potentiates the effect of adrenaline on the
carotid mechanism. Other workers, attempting
to explain the effectiveness of chloroquine in
diseases related to light-sensitivity, have investi-
gated its light absorption properties, Langlo (24),
demonstrated some inhibition of UVL erythema
by chloroquine applied topically as a 5% oint-
ment, and Tronnier and Azimi-Hamid (25) have
shown some inhibition by the drug administered
internally and have convincingly related this
action to the presence of the alkyl side-chain it
possesses in common with quinacrine.
The UVL absorption spectrum of ch]oroquine
corresponds to the range Beal (26) demonstrated
to be responsible for 2 eases of solar urticaria.
Cahn, et al. (27), however, were not only unable
to demonstrate any change in the minimal
erythema dose of UVL in subjects taking chloro-
quine at or above therapeutic levels, but were
also able to prove that the wave lengths causing
polymorphous light eruption did not correspond
to those against which ehloroquine might be ex-
pected to protect their patients. They concluded
that the sun-screening action of the drug was not
responsible for its therapeutic effect in this
disease.
An "anti-inflammatory" action has been re-
ported for chloroquine by Blaich and Gerlach
(28). Nagy (29) and his group, working with
quinacrine, showed that guinea pigs and cats pre-
treated with this drug could withstand doses of
histamine lethal to untreated controls. Searching
for the cause of this "anti-histaminic" effect,
they found that the lung histaminase activity of
quinacrine-treated guinea pigs was the same as
that of controls. They did find, however, that
the adrenal glands of the quinacrine-treated
guinea pigs were markedly enlarged. Histological
examination showed that the cortex was hyper-
trophied and in the secretory phase. They re-
ported a 30% increase in 17-ketosteroid produc-
tion in the treated group. From this evidence in
the guinea pig, Nagy, et al. proposed that stimu-
lation of the adrenal cortex to increased hormone
production might play a role in the mechanism
of the therapeutic action of quinacrine. Leoni,
et al. (30) reported some drop in the eosinophile
count of human subjects at the time of maxi-
mum absorption of a single dose of chloroquine.
However, since this effect did not occur in all
subjects nor correlate with their test for "anti-
inflammatory" action they concluded that the
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TABLE 2
Tabulation of Eosinophile Counts in the Control Group Receiving Calcium Lactate
Subj. No. Eosjnophiles/mm3
1
2
123
158
97
219
136
187
137
223
93
234
70
211
75
152
122
212
108
158
153 86
197 231
153
222
197
219
78
288
71
184
125
194
3 228 278 208 263 155 166 208 284 172 278 199 216 229 197 219 194
4 166 219 150 102 178 161 152 233 162 216 216 159 197 140 147 144
5 148 228 119 114 180 100 145 294 191 206 128 303 159 97 119 269
6 216 227 162 247 116 141 250 180 178 356 256 206 206 225 344 150
7 116 186 98 125 134 100 120 128 94 176 88 109 144 113 184 134
8 303 212 167 261 144 152 206 150 312 173 275 219 263 172 128 328
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FIG. 2. Graph of the control data for figure 1.
Eosinophile counts in subjects receiving calcium
lactate (975 mgm/day for 28 days).
action of chloroquine was not cortisone-like.
Studies of the chronic human toxicity of chloro-
quine (31), and reports of long-term clinical
trials do not include information about adreno-
cortical function. Nelson and Fitzhugh (32), in
their thorough investigation of chronic chloro-
quine toxicity in rats, noted that the adrenals
were normal except for changes due to inanition.
Thies (33) has reported that locally-injected
chloroquine is an effective therapy in chronic
discoid lupus erythematosus and Ottolenghi-
Lodigiani (34) has reported similar results for
quinacrine.
With this background of promising but contra-
dictory evidence, we undertook the present study
of the effect of long-term, high dosage chlosoquine
administration on the function of the normal
human adrenal cortex.
METHOD OF RESEARCH
Subjects. Two groups of 8 healthy male inmates
of a penal institution, age 20 to 50, were randomly
selected. The test group contained 3 Negroes,
the control group 2.
Dosage. The test group received three 250 mg.
enteric-coated tablets of cliloroquine-phosphate
(total—750 mg.) daily at 11:00A.M. for 28 days.
The control group received three 325 mg. tablets
of calcium lactate (placebo) daily at the same
hour for the same period.
Eosinophile counts. Five cc. of venous blood
were collected using the anticoagulant, dilution,
and counting methods described by Thorn ci al.
(35). The number of eosinophiles reported per
mm3 represents the average of four counts. The
initial sample was taken just prior to the first
dosage of chloroquine or placebo, the second
sample 4 hours later. Subsequent samples, taken
1,2,3,4,5,6,8, 12, 15, 20, 22, 26, 28, and 42
days after the start of testing, were drawn at the
same hour as the second sample (3:00 P.M.),
with the exception of the twentieth day sample
which was taken at 11:00 A.M. Spot-check re-
counts showed minimal variation from the
reported figures.
White cell counts. Using standard laboratory
technic, total white cell counts were performed
using the blood drawn for the 15 and 26-day
eosinophile counts.
Steroid assays. A 24-hour urine specimen was
collected under chloroform, starting at 11:00
A.M. on the 27th test day, from the test
group only. 17-Ketosteroids were assayed by the
technic of Zimmerman (36) and 17-hydroxycorti-
costeroids by the technic of Silber and Porter
(37).
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TABLE 3
Comparison of Eosinophile and Total White Cell Count in Chloroquine and Placebo Treated
Groups on the Fifteenth and Twenty-Sixth Days of Treatment
Chioroquine Placebo
Subj. WBC Eo. WBC Eo. Subj.
-
WBC
-
Eo. WBC Eo.
1 6100 147 4400 144 1 4700 86 3650 78
2 5300 156 6200 97 2 4550 231 4800 288
3 4200 259 4800 88 3 4850 199 4600 197
4 4650 122 5600 113 4 4900 216 4800 140
5 3900 88 5400 100 5 5050 128 6750 97
6 6450 241 3800 141 6 6800 256 5200 225
7 4650 150 4050 94 7 5200 88 4550 113
8 6350 247
15 days
4000 134
26 days
8 4100 275
15 days
3000 172
26 days
TABLE 4
Tabulation of 24-Hour Urinary Excretion Values for 17-Hydroxycorticoids and 17-Ketosteroids
in Chloroquine-Treated Group. Determinations Were All Made on the Twenty-Eighth
Day o.f Treatment
17-Hydroxycortieoids (Mg/24
h.) 6.2 6.2 7.1 4.9 7.5 3.6 8.3 3.1
17-Ketosteroids (Mg/24 h.) 15.0 5.3 7.4 11.8 6.3 2.0 17.3 6.8
RESULTS
Complaints of headache and gastro-intestinal
disturbance were no more common in the test
group than among the controls, but complaints
of visual disturbance, while more common in the
test group, were also made by the controls. Sub-
jects were otherwise apparently healthy through-
out the test period.
Eosinophile counts for the test group are pre-
sented in Table 1 and Figure 1, and for the con-
trol group in Table 2 and Figure 2. Any signifi-
cance attributed to variations in the eosinophile
level among the test group must be evaluated in
the light of variations seen in the control group.
Among the latter, fluctuations of the order of
50% are seen at different times in several of the
subjects, and wide variation is usual, rather than
exceptional. The same pattern generally applies
to the test group. When both groups are plotted
graphically they are seen to maintain a rather
uniform group pattern. Seen thus we feel that no
significant depression of the eosinophile count
can be claimed to follow ehloroquine administra-
tion in normal human subjects under the above
test conditions.
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Fin. 3. Histogram presenting urinary excretion
values for 17-hydroxycorticoids in test group on
the twenty-eighth day of chioroquine therapy.
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FIG. 4. Histogram presenting urinary excretion
values for 17-ketosteroids in test group on the
twenty-eighth day of chioroquine therapy.
Table 3 compares the eosinophile counts taken
on the 15th and 26th days of the test period with
total white cell counts taken from the same blood
samples. The two values are seen to be inde-
pendently variable.
Table 4 and Figures 3 and 4 present the results
of 17-hydroxycorticosteroid and 17-ketosteroid
determinations made on a 24-hour urine specimen
collected on the 27th test day. Thorn et at. (38)
state that a change in total 17-hydroxycorticoid
excretion is a more reliable indicator of adrenal
cortical activity than an alteration in 17-kcto-
steroids. It will be seen that all the test subjects'
17-hydroxycorticostcroids fell well within normal
limits. Low values for 17-kctosteroids in 5 of 8
test subj ects may be related to Nelson and
Fitzhugh's (32) finding that the rat testicle
showed marked atrophy in response to prolonged
chloroquine administration. Our own findings of
low or normal steroid levels show that chloroquinc
does not increase adrenocortical activity.
COMMENT
A review of the literature has shown that
chloroquine's therapeutic mechanism may be rc-
latcd to its nuclco-protcin binding property, to
its interference with a number of biochemical
systems, or to its light-screening properties.
Some objections to each of these theories have
been previously discussed. The proposal of Nagy's
group that chloroquinc may act indirectly by
stimulating the adrenal cortex to increased
activity has not been substantiated by our find-
ings in human subjects. At present the mode of
action of chloroquinc, particularly in the light-
sensitive dermatoscs remains obscure. The influ-
ence of this drug on known biochemical processes,
perhaps on the redox potential which Langhof
and Muting (39) believe to play a key role in
light-sensitive diseases, would seem to offer an
interesting field for research.
SUMMARY
(1) A report is given of an investigation of the
effect of long term, high-dosage chloroquine on
human adrcno-cortical activity.
(2) Eosinophilc counts and corticosteroid
assays indicated no increase in adrenal activity
during one month of chloroquinc therapy.
(3) Lowered 17-kctostcroid values in 5 of S
subjects may reflect a depression of testicular
activity caused by chloroquine.(4) It is concluded that the therapeutic
mechanism of action of chloroquinc does not
involve the adrenal cortex.
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